Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)

626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) - Results from Prospective Clinical Trials:

Updates and advances in bispecific antibody therapies and autologous CAR-T approaches

 

Watch Session

400 Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

Rajat Bannerji, John N. Allan, Jon E. Arnason, et al. 

 

401 Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B‑Cell Lymphoma

Adam J Olszewski, Abraham Avigdor, Sunil Babu, et al.

 

402 Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, Rogier Mous, Michael Roost Clausen, et al.

 

403 Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Martin Hutchings, Carmelo Carlo-Stella, Emmanuel Bachy, et al.

 

404 Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Peter Borchmann, Anja Jühling, Philipp Gödel, et al.

 

405 Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL) according to ASH clinically relevant abstract

Sattva S. Neelapu, Michael Dickinson, Matthew L. Ulrickson, et al.